Dublin, Feb. 26, 2024 (GLOBE NEWSWIRE) -- The "Global Venous Thromboembolism Treatment Market by Device (Thrombectomy, Inferior Vena Cava Filter [Retrievable, Permanent], Stockings, Compression Pump) Application (DVT, Pulmonary Embolism) End User (Hospital, Ambulatory Care Center) - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
The global venous thromboembolism treatment market is projected to reach $4.40 billion by 2030, at a CAGR of 7.2% from 2023 to 2030.
After conducting an extensive primary and secondary study and an in-depth analysis of the market scenario, this report offers insights into the key drivers, constraints, challenges, and opportunities within the venous thromboembolism treatment market.
The high prevalence of venous thromboembolism, rising incidence of cancer, growing prevalence of secondary risk factors such as diabetes and obesity, increase in orthopedic surgical procedures, and the rising demand for minimally invasive treatment procedures are the key factors driving the growth of the venous thromboembolism treatment market. Furthermore, the growing accessibility and affordability of treatment options, advancements in VTE diagnosis and treatment methods, and the market expansion in emerging economies are expected to create market growth opportunities.
However, instances of product failure and product recalls may restrain the market's growth. Additionally, lack of awareness about venous thromboembolism and increasing awareness of probable side effects of compression garments are major challenges for market growth.
Among the devices covered in this report, in 2023, the thrombectomy devices segment is expected to account for the largest share of the venous thromboembolism treatment market. The large market share of this segment is attributed to the increasing prevalence of cardiovascular diseases, growing preference for minimally invasive procedures, and launches of new thrombectomy devices.
Among the applications covered in this report, in 2023, the deep vein thrombosis segment is expected to account for the largest share of the venous thromboembolism treatment market. The large market share of this segment is attributed to the increasing prevalence of obesity, a growing geriatric population, rising cases of deep vein thrombosis due to lifestyle-related diseases, excessive alcohol consumption, and heightened awareness of DVT.
Among the end users covered in this report, in 2023, the hospitals segment is expected to account for the largest share of the venous thromboembolism treatment market. The large market share is attributed to the increasing prevalence of venous thromboembolism, the rising number of hospitals and clinics, the presence of highly skilled professionals, and the high purchasing power of hospitals. The easy accessibility to hospitals, coupled with a large patient population seeking comprehensive healthcare services, including diagnosis, treatment, and surgeries at a single location, also contributes to the significant market share of this segment.
In 2023, North America is expected to account for the largest share of the global venous thromboembolism treatment market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
However, Asia-Pacific is slated to register the largest CAGR during the forecast period. The growth of this regional market can be attributed to factors such as the growing prevalence of chronic diseases, the increasing number of people living sedentary lifestyles, growing health expenditures, supportive government initiatives aimed at improving healthcare infrastructure, and rising awareness regarding venous thromboembolism.
Market Insights
Drivers
- High Prevalence of Venous Thromboembolism
- Rising Incidence of Cancer
Restraints
- Instances of Product Failure and Product Recalls
Opportunities
- Growing Accessibility and Affordability of Treatment Options
- Advancements in VTE Diagnosis and Treatment Methods
Challenges
- Lack of Awareness About Venous Thromboembolism
Competition Analysis
Key Growth Strategies
- Competitive Benchmarking
- Competitive Dashboard
- Industry Leaders
- Market Differentiators
- Vanguards
- Emerging Companies
Market Share Analysis (2022)
- Boston Scientific Corporation (U.S.)
- Stryker Corporation (U.S.)
- Cardinal Health, Inc. (U.S.)
- Enovis Corporation (U.S.)
- Medtronic plc (Ireland)
- Cook Group Incorporated (U.S.)
Company Profiles
- ALN Implants chirurgicaux (ALN Surgical Implants)
- AngioDynamics, Inc.
- Argon Medical Devices, Inc.
- ArjoHuntleigh AB
- Boston Scientific Corporation
- Cardinal Health, Inc.
- Cook Group Incorporated
- Koninklijke Philips N.V.
- DS MAREF Co., Ltd
- Enovis Corporation
- LifeTech Scientific Corporation
- Medtronic plc
- Stryker Corporation
Scope of the Report:
Venous Thromboembolism Treatment Market Assessment - by Device
- Thrombectomy Devices
- Inferior Vena Cava Filters
- Retrievable Filters
- Permanent Filters
- Stockings
- Compression Pumps
- Other Devices & Accessories
Venous Thromboembolism Treatment Market Assessment - by Application
- Deep Vein Thrombosis
- Pulmonary Embolism
Venous Thromboembolism Treatment Market Assessment - by End User
- Hospitals
- Ambulatory Care Centers
- Other End Users
Venous Thromboembolism Treatment Market Assessment - by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
For more information about this report visit https://www.researchandmarkets.com/r/grzedh
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
